Quel est le prix pour TME Pharma N.V. (ALTME)

Le prix pour TME Pharma N.V. (ALTME) est $0.07603255

Quelle est la capitalisation boursière pour TME Pharma N.V. (ALTME)

La capitalisation boursière pour TME Pharma N.V. (ALTME) est $7.16M

TME Pharma N.V. (ALTME) Rendement du Dividende

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.

Année	Rendement du dividende	Changez
Pas assez de données pour les dates fournies.

Année

Rendement du dividende

Changez

Pas assez de données pour les dates fournies.

Entreprise	Rendement du dividende	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.48%	BE

Entreprise

Rendement du dividende

Pays